Open Label Treatment Extension Study With SAR245408 or SAR245409 as a Monotherapy or as a Combination Regimen

Neoplasm Malignant Clinical Trial

Official title:

International, Multicenter, Open-label, Treatment-extension Study for Subjects Who Completed a Phase 1 or Phase 2 Parental Study to Continue Receiving Treatment With SAR245408 or SAR245409 as a Monotherapy or as a Combination Regimen

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01587040
• Other study ID #: TED12414
• Secondary ID: 2011-006140-78U1
• Status: Completed
• Phase: Phase 1/Phase 2
• Start date: July 20, 2012
• Est. completion date: May 23, 2018

Study information

• Verified date: March 2022
• Source: Sanofi
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Primary Objective:

The purpose of this study was to determine the long term safety and tolerability of SAR245408 and SAR245409 as a monotherapy or as part of a combination regimen in participants who were benefiting from treatment.

Description:

The duration of the study for an individual participant included:

1. Baseline assessments: within 7 days prior to the first dose of investigational medicinal product (IMP).

2. Study treatment period(s):

Participants started study treatment at the beginning of the initiation or extension periods based on the length of prior therapy with SAR245408 or SAR245409

• if <2 cycles, started with initiation period; Participant must have had completed all the visits in the initiation period before moving to the extension period.

• if >=2 cycles, started with extension period; duration of extension period was unlimited.

• Participants who took a SAR245408 or SAR245409 daily dose higher than their established dose of SAR245408 or SAR245409, respectively, in the parental study entered the study on Day 1 of the initiation period.

• Participants who had dose interrupted in the parental study but fulfilled parental protocol criteria to restart IMP treatment entered the treatment-extension study on Day 1 of the initiation period.

• Participants who fulfilled the parental study criteria for IMP treatment continuation but had ongoing Grade 2 adverse events (AEs) entered the treatment-extension study on Day 1 of the initiation period.

Participants continued to receive study treatment until disease progression, unacceptable toxicity, withdrawal of consent, or until commercial supplies of SAR245408 or SAR245409 were available to them outside of the clinical trial.

3. Follow-up assessments: 23 to 37 days after the last dose of IMP.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 61
• Est. completion date: May 23, 2018
• Est. primary completion date: May 23, 2018
• Accepts healthy volunteers: No
• Gender: All
• Age group: N/A and older

Eligibility

Inclusion criteria :

I 01. Males or females enrolled in Phase 1 or Phase 2 studies of SAR245408 or SAR245409 as monotherapy or in combination with other regimens who had completed data collection for the primary endpoint(s) of the parental study or who were being treated beyond the parental study cut-off and meet all the criteria to continue to be treated per the parental protocol.

I 02. All sexually active participants (male and female) must agreed to continue to use accepted methods of barrier contraception (i.e., condoms) during the course of the study and for 3 months after discontinuation of study treatment. For women of childbearing potential and for men who could father a child, a second method of contraception in addition to a barrier method is recommended. Hormonal contraception should be avoided in participants taking SAR245408 due to possible drug-drug interaction.

I 03. Female participants of childbearing potential must had a negative pregnancy test at baseline. Females of childbearing potential were defined as sexually mature women without prior hysterectomy or who had any evidence of menses in the past 12 months. However, women who had been amenorrheic for 12 or more months were still considered to be of childbearing potential if the amenorrhea was possibly due to other causes, including prior chemotherapy, anti-estrogens, or ovarian suppression.

Exclusion criteria:

E 01. The participant discontinued the parental study due to toxicity. E 02. Ongoing Grade 3 or higher Adverse Event (AE). E 03. Ongoing Serious Adverse Event (SAE). E 04. Participants with ongoing dose interruption for any reason unless the participant fulfilled the criteria in the parental protocol for restarting IMP. In such case participant started the treatment-extension study on Day 1 of the initiation period.

E 05. The participant had any of the following laboratory values = Common Terminology of Adverse Events (CTCAE) Grade 3

• Absolute neutrophil count (ANC),

• Platelet count,

• Hemoglobin,

• Bilirubin,

• Serum creatinine or calculated creatinine clearance,

• Alanine aminotransferase (ALT) and aspartate aminotransferase (AST),

• Fasting plasma glucose (FPG),

• Prothrombin time/international normalized ratio (PT/INR) and activated partial thromboplastin time (aPTT).

E 06. The participant had a baseline corrected QT interval (QTc) >481 millisecond (msec) or if a participant has had a QTc interval increase of = 60 msec from parental protocol baseline to an absolute value of > 470 msec.

E 07. The participant had a known allergy or hypersensitivity to components of the study treatment formulation(s).

E 08. The participant was pregnant or breastfeeding.

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Related Conditions & MeSH terms

• Neoplasm Malignant
• Neoplasms

Intervention

Drug:
• SAR245408
Pharmaceutical form: capsule or tablet Route of administration: oral
• SAR245409
Pharmaceutical form: capsule or tablet Route of administration: oral

Locations

Country	Name	City	State
Belgium	Investigational Site Number 056001	Leuven
France	Investigational Site Number 250004	Montpellier
France	Investigational Site Number 250003	Pierre Benite Cedex
France	Investigational Site Number 250005	Rouen Cedex
Spain	Investigational Site Number 724001	Barcelona
United States	Investigational Site Number 840006	Augusta	Georgia
United States	Investigational Site Number 840010	Birmingham	Alabama
United States	Investigational Site Number 840004	Boston	Massachusetts
United States	Investigational Site Number 840020	Canton	Ohio
United States	Investigational Site Number 840015	Columbus	Ohio
United States	Investigational Site Number 840003	Dallas	Texas
United States	Investigational Site Number 840022	Denver	Colorado
United States	Investigational Site Number 840104	Fort Myers	Florida
United States	Investigational Site Number 840008	Los Angeles	California
United States	Investigational Site Number 840009	Los Angeles	California
United States	Investigational Site Number 840018	Morgantown	West Virginia
United States	Investigational Site Number 840007	Nashville	Tennessee
United States	Investigational Site Number 840002	New Brunswick	New Jersey
United States	Investigational Site Number 840017	Philadelphia	Pennsylvania
United States	Investigational Site Number 840021	Saint Louis	Missouri
United States	Investigational Site Number 840005	San Antonio	Texas

Sponsors (1)

Lead Sponsor	Collaborator
Sanofi

Countries where clinical trial is conducted

United States,  Belgium,  France,  Spain, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of Participants With Treatment Emergent Adverse Events (TEAEs)	Any untoward medical occurrence in a participant who received IMP was considered an AE without regard to possibility of causal relationship with this treatment. Serious adverse event (SAE): any untoward medical occurrence that resulted in any of the following outcomes: death, life-threatening, required initial/prolonged in-patient hospitalization, persistent/significant disability/incapacity, congenital anomaly/birth defect/considered as medically important event. TEAEs: AEs that developed/worsened/became serious during on-treatment period (time from IMP until 30 days after last dose of any IMP). Any TEAE included participants with both SAE & non-SAEs. TEAE included participants with any treatment-emergent SAE (TESAE). TEAEs that led to death, dose reduction and/or delay, discontinuation & AEs related to treatment were reported. Grades (3=severe, 4=life-threatening/disabling) represents severity of AEs.	From Baseline up to 30 days after the last dose (maximum exposure: 1959 days)
Primary	Number of Participants With Potentially Clinically Significant Laboratory Abnormalities: Hematological Parameters	Hematological parameters assessed were anemia, neutropenia and thrombocytopenia. Parameters were assessed as per the National Cancer Institute Common Terminology Criteria for Adverse Experience version 4.03 (NCI-CTCAE v 4.03), where Grade 1 = Mild; Grade 2 = Moderate; Grade 3 = Severe; Grade 4 = Potentially Life Threatening. Grade refers to the severity of the AEs.	From Baseline up to 30 days after the last dose (maximum exposure: 1959 days)
Primary	Number of Participants With Potentially Clinically Significant Laboratory Abnormalities: Biochemical Parameters	Biochemical parameters assessed were hyperglycemia, aspartate aminotransferase (ASAT) increased, alanine aminotransferase (ALAT) increased, hyperbilirubinemia, hypocalcemia, creatinine increased. Parameters were assessed as per the NCI-CTCAE v 4.03, where Grade 1 = Mild; Grade 2 = Moderate; Grade 3 = Severe; Grade 4 = Potentially Life Threatening. Grade refers to the severity of the AEs.	From Baseline up to 30 days after the last dose (maximum exposure: 1959 days)